Dyne Therapeutics Stock Analysis

Dyne Stock Analysis Notes

About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Dyne Therapeutics was currently reported as 6.93. The company has Price/Earnings To Growth (PEG) ratio of 0.19. Dyne Therapeutics recorded a loss per share of 3.58. The entity last dividend was issued on the May 30, 2002. The firm had 1:5 split on the May 25, 2010. Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.. Dyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people. To learn more about Dyne Therapeutics call Joshua Brumm at 781 786 8230 or check out https://www.dyne-tx.com.

Dyne Therapeutics Investment Alerts

Dyne Therapeutics Upcoming and Recent Events

Dyne Largest EPS Surprises

View All Earnings Estimates

Dyne Therapeutics Environmental, Social, and Governance (ESG) Scores

Dyne Stock Institutional Investors

Note, although Dyne Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Dyne Market Capitalization

The company currently falls under 'Mid-Cap' category with a total capitalization of 3.17 B.

Dyne Profitablity

Management Efficiency

Dyne Therapeutics has Return on Asset of (0.4035) % which means that on every $100 spent on assets, it lost $0.4035. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6868) %, meaning that it generated no profit with money invested by stockholders. Dyne Therapeutics' management efficiency ratios could be used to measure how well Dyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to grow to -1.36. In addition to that, Return On Capital Employed is likely to grow to -2.02. As of the 29th of November 2024, Debt To Assets is likely to grow to 0.26, while Total Assets are likely to drop about 156.8 M.

Technical Drivers

As of the 29th of November, Dyne Therapeutics shows the Standard Deviation of 5.39, variance of 29.06, and Mean Deviation of 3.1. Dyne Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Dyne Therapeutics Price Movement Analysis

Dyne Therapeutics Insider Trading Activities

Dyne Therapeutics Outstanding Bonds

Dyne Therapeutics Predictive Daily Indicators

Dyne Therapeutics Corporate Filings

Dyne Therapeutics Forecast Models

Dyne Therapeutics' time-series forecasting models are one of many Dyne Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dyne Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Dyne Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dyne shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dyne Therapeutics. By using and applying Dyne Stock analysis, traders can create a robust methodology for identifying Dyne entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dyne analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dyne analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Dyne Therapeutics stock analysis indicators help investors evaluate how Dyne Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dyne Therapeutics shares will generate the highest return on investment. By understating and applying Dyne Therapeutics stock analysis, traders can identify Dyne Therapeutics position entry and exit signals to maximize returns.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.